These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 15688597)

  • 21. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib: proteasome inhibition as an effective anticancer therapy.
    Richardson PG; Mitsiades C
    Future Oncol; 2005 Apr; 1(2):161-71. PubMed ID: 16555986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
    Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of bortezomib in the treatment of multiple myeloma.
    Cavo M
    Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging trends in the clinical use of bortezomib in multiple myeloma.
    Richardson PG; Schlossman R; Mitsiades C; Hideshima T; Munshi N; Anderson K
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):84-8. PubMed ID: 16231845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Proteasome inhibitors].
    Hatake K; Mishima Y; Terui Y
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ubiquitin proteasome pathway from bench to bedside.
    Orlowski RZ
    Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
    Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential role of proteasome inhibitors in the treatment of lung cancer.
    Bunn PA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib for multiple myeloma.
    Popat R; Joel S; Oakervee H; Cavenagh J
    Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
    Richardson PG; Hideshima T; Anderson KC
    Cancer Control; 2003; 10(5):361-9. PubMed ID: 14581890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of proteasome inhibitors as anticancer drugs.
    Adams J
    Cancer Cell; 2004 May; 5(5):417-21. PubMed ID: 15144949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
    Tobinai K
    Int J Clin Oncol; 2007 Oct; 12(5):318-26. PubMed ID: 17929113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Proteasome inhibitors].
    Saeki Y; Fukunaga K; Tanaka K
    Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel treatment approaches for patients with multiple myeloma.
    Sinha R; Kaufman JL; Lonial S
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):281-8. PubMed ID: 16507205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the proteasome inhibitor bortezomib in hematologic malignancies.
    Goy A; Gilles F
    Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.